Trial Profile
Phase II Trial of Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Therapeutic Use
- Acronyms NIVO-ALCL
- 09 Oct 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Dec 2023.
- 01 Jul 2021 Planned End Date changed from 1 Jan 2027 to 1 Jun 2028.
- 01 Jul 2021 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2023.